Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors

Scandinavian Journal of Infectious Diseases

Volumn 34, Issue 5, 2002, Pages 347-350

  Ljungman, Per ^a   Larsson, Kajsa ^a   Kumlien, Gunilla ^a   Aschan, Johan ^a   Barkholt, Lisbeth ^a   Gustafsson Jernberg, Åsa ^a   Lewensohn Fuchs, Ilona ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHOTREXATE; VIRUS DNA;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD FILTRATION; BLOOD STORAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; DONOR; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; LEUKOPENIA; PATIENT MONITORING; POLYMERASE CHAIN REACTION; RECIPIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; SAFETY; SCREENING TEST; STEM CELL TRANSPLANTATION; ADOLESCENT; ALLOTRANSPLANTATION; APHERESIS; BLOOD DONOR; CHILD; CYTOMEGALIC INCLUSION BODY DISEASE; FILTRATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; ISOLATION AND PURIFICATION; LYMPHOCYTE DEPLETION; MIDDLE AGED; PRESCHOOL CHILD;

ADOLESCENT; ADULT; BLOOD COMPONENT REMOVAL; BLOOD DONORS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FILTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LEUKOCYTES; LYMPHOCYTE DEPLETION; MIDDLE AGE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; TRANSPLANTATION, HOMOLOGOUS; HUMANS; MIDDLE AGED;

EID: 0035987162     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540110080412     Document Type: Article

References (25)

1. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation
2. Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant
3. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients
4. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients
5. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings
6. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia
7. Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow
8. Evaluation of platelets prepared by apheresis and stored for five days. In vitro and in vivo studies
9. A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with "split" apheresis single donor platelets
10. Storage of platelets in additive solutions: Effects of phosphate
11. CMV PCR monitoring in leukocytes of transplant patients
12. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients
13. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: A report from the Working Party for Infectious Diseases of the EBMT
14. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells
15. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes
16. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors
17. Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients
18. Early occurrence of HCMV infection after BMT as demonstrated by the PCR technique
19. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
20. A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood
21. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time
22. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors
23. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients
24. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
25. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors